Shares of Jaguar Health (JAGX) are currently trading higher in the pre-market, as we recently reported that the company revealed the sale of $6 million in Mytesi royalties to a secured lender last week.
A pharmaceuticals company focused on developing sustainable, novel gastrointestinal products, and Jaguar Health Inc is currently commercial-stage.
Before the market opened today, Jaguar Health’s (JAGX) share was trading at an increased price of $0.833, which was higher by 16.08%. The average volume for the stock during the last three-month period was 30.40 million. However, its shares are trading at a distance of 82.52% from its 20-days Simple Moving Average.